Gold drug auranofin could reduce neuroinflammation by inhibiting microglia cytotoxic secretions and primed respiratory burst

Journal of Neuroimmunology

Volumn 276, Issue 1-2, 2014, Pages 71-79

  Madeira, Jocelyn M ^a   Bajwa, Ekta ^a   Stuart, Maegan J ^a   Hashioka, Sadayuki ^b,c   Klegeris, Andis ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SHIMANE UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Aurothiomalate; Aurothiosulfate; Neuroprotection; Parkinson's disease; Respiratory burst priming

Indexed keywords

AURANOFIN; NITRIC OXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; CYTOKINE; LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDE; REACTIVE OXYGEN METABOLITE;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DEGENERATIVE DISEASE; DRUG EFFECT; HUMAN; HUMAN CELL; MICROGLIA; MONOCYTE; NERVE CELL; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; RESPIRATORY BURST; ANIMAL; CELL CULTURE; CELL SURVIVAL; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; GRANULOCYTE PRECURSOR; METABOLISM; MOUSE; NEUROBLASTOMA; PATHOLOGY; SECRETION (PROCESS); TEMPORAL LOBE; TIME;

ANIMALS; ANTIRHEUMATIC AGENTS; AURANOFIN; CELL SURVIVAL; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GRANULOCYTE PRECURSOR CELLS; HUMANS; L-LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDES; MICE; MICROGLIA; MONOCYTES; NADPH OXIDASE; NEUROBLASTOMA; NITRIC OXIDE; REACTIVE OXYGEN SPECIES; RESPIRATORY BURST; TEMPORAL LOBE; TIME FACTORS;

EID: 84908508871     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.08.615     Document Type: Article

References (59)

1. Abramson S.L., Gallin J.I. IL-4 inhibits superoxide production by human mononuclear phagocytes. J. Immunol. 1990, 144:625-630.
2. Anderson R., Van Rensburg C.E., Joone G.K., Lessing A. Auranofin inactivates phosphofructokinase in human neutrophils, leading to depletion of intracellular ATP and inhibition of superoxide generation and locomotion. Mol. Pharmacol. 1991, 40:427-434.
3. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Immunol. 2007, 8:57-69.
4. Brodie C., Goldreich N., Haiman T., Kazimirsky G. Functional IL-4 receptors on mouse astrocytes: IL-4 inhibits astrocyte activation and induces NGF secretion. J. Neuroimmunol. 1998, 81:20-30.
5. Brown G. Nitric oxide and neuronal death. Nitric Oxide 2010, 23:153-165.
6. Bruze M., Björkner B., Möller H. Skin testing with gold sodium thiomalate and gold sodium thiosulfate. Contact Dermatitis 1995, 32:5-8.
7. Cameron B., Landreth G.E. Inflammation, microglia, and Alzheimer's disease. Neurobiol. Dis. 2010, 37:503-509.
8. Champion G.D., Graham G.G., Ziegler J.B. The gold complexes. Baillieres Clin. Rheumatol. 1990, 4:491-534.
9. Chomarat P., Banchereau J. Interleukin-4 and interleukin-13: their similarities and discrepancies. Int. Rev. Immunol. 1998, 17:1-52.
10. Cornelius C., Crupi R., Calabrese V., Graziano A., Milone P., Pennisi G., Radak Z., Calabrese E.J., Cuzzocrea S. Traumatic brain injury: oxidative stress and neuroprotection. Antioxid. Redox Signal. 2013, 19:836-853.
11. Dajas F., Rivera F., Blasina F., Arredondo F., Echeverry C., Lafon L., Morquio A., Heinzen H. Cell culture protection and in vivo neuroprotective capacity of flavonoids. Neurotox. Res. 2003, 5:425-432.
12. Decker T., Lohmann-Matthes M.L. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Methods 1988, 115:61-69.
13. Ding A.H., Nathan C.F., Stuehr D.J. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J. Immunol. 1988, 141:2407-2412.
14. Ellingsen T., Buus A., Stengaard-Pedersen K. Plasma monocyte chemoattractant protein 1 is a marker for joint inflammation in rheumatoid arthritis. J. Rheumatol. 2001, 28:41-46.
15. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis - the plaque and its pathogenesis. N. Engl. J. Med. 2006, 354:942-955.
16. Gao H.M., Zhou H., Hong J.S. NADPH oxidases: novel therapeutic targets for neurodegenerative diseases. Trends Pharmacol. Sci. 2012, 33:295-303.
17. Gibbons H., Dragunow M. Microglia induce neural cell death via a proximity-dependent mechanism involving nitric oxide. Brain Res. 2006, 1084:1-15.
18. Glennas A., Kvien T.K., Andrup O., Clarke-Jenssen O., Karstensen B., Brodin U. Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis. Br. J. Rheumatol. 1997, 36:870-877.
19. Graham G.G., Champion G.D., Ziegler J.B. The cellular metabolism and effects of gold complexes. Metal-Based Drugs 1994, 1:395-404.
20. Hansen M.B., Nielsen S.E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 1989, 119:203-210.
21. Hashioka S., Klegeris A., McGeer P.L. Proton pump inhibitors exert anti-inflammatory effects and decrease human microglial and monocytic THP-1 cell neurotoxicity. Exp. Neurol. 2009, 217:177-183.
22. Heneka M.T., O'Banion M.K., Terwel D., Kummer M.P. Neuroinflammatory processes in Alzheimer's disease. J. Neural Transm. 2010, 117:919-947.
23. Jeon K.I., Jeong J.Y., Jue D.M. Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase. J. Immunol. 2000, 164:5981-5989.
24. Kean W.F. Intramuscular versus oral gold therapy. Baillieres Clin. Rheumatol. 1990, 4:219-246.
25. Kean W.F., Hart L., Buchanan W.W. Auranofin. Br. J. Rheumatol. 1997, 36:560-572.
26. Kim N.H., Lee M.Y., Park S.J., Choi J.S., Oh M.K., Kim I.S. Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3. Immunology 2007, 122:607-614.
27. Kim N.H., Oh M.K., Park H.J., Kim I.S. Auranofin, a gold (I)-containing antirheumatic compound, activates Keap1/Nrf2 signaling via Rac1/iNOS signal and mitogen-activated protein kinase activation. J. Pharmacol. Sci. 2010, 113:246-254.
28. Klegeris A., Bissonnette C.J., McGeer P.L. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br. J. Pharmacol. 2003, 139:775-786.
29. Klegeris A., Bissonnette C.J., McGeer P.L. Modulation of human microglia and THP-1 cell toxicity by cytokines endogenous to the nervous system. Neurobiol. Aging 2005, 26:673-682.
30. Klegeris A., McGeer E.G., McGeer P.L. Therapeutic approaches to inflammation in neurodegenerative disease. Curr. Opin. Neurol. 2007, 20:351-357.
31. Kortekaas R., Leenders K.L., van Oostrom J.C., Vaalburg W., Bart J., Willemsen A.T., Hendrikse N.H. Blood-brain barrier dysfunction in Parkinsonian midbrain in vivo. Ann. Neurol. 2005, 57:176-179.
32. Krause D., Suh H.S., Tarassishin L., Cui Q.L., Durafourt B.A., Choi N., Bauman A., Cosenza-Nashat M., Antel J.P., Zhao M.L., Lee S.C. The tryptophan metabolite 3-hydroxyanthranilic acid plays anti-inflammatory and neuroprotective roles during inflammation: role of hemeoxygenase-1. Am. J. Pathol. 2011, 179:1360-1372.
33. Lee Y.J., Han S.B., Nam S.Y., Oh K.W., Hong J.T. Inflammation and Alzheimer's disease. Arch. Pharm. Res. 2010, 33:1539-1556.
34. Lee C.W., Ko H.H., Lin C.C., Chai C.Y., Chen W.T., Yen F.L. Artocarpin attenuates ultraviolet B-induced skin damage in hairless mice by antioxidant and anti-inflammatory effect. Food Chem. Toxicol. 2013, 60:123-129.
35. Li C., Zhao R., Gao K., Wei Z., Yin M.Y., Lau L.T., Chui D., Hoi Yu A.C. Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 2011, 8:67-80.
36. Lu D., Shao H.T., Ge W.P., Liu N., Zhang X., Ma C.M., Qin C., Zhang L.F. Ginsenoside-RB1 and tetramethylpyrazine phosphate act synergistically to prevent dilated cardiomyopathy in cTnTR141W transgenic mice. J. Cardiovasc. Pharmacol. 2012, 59:426-433.
37. Lull M.E., Block M.L. Microglial activation and chronic neurodegeneration. Neurotherapeutics 2010, 7:354-365.
38. Madeira J.M., Gibson D.L., Kean W.F., Klegeris A. The biological activity of auranofin: implications for novel treatment of diseases. Inflammopharmacology 2012, 20:297-306.
39. Madeira J.M., Little J.P., Klegeris A. Microglia secretome: from neurotoxins to neurotrophins. Microglia: Biology, Functions and Roles in Disease 2012, 73-92. Nova Publishers, New York. C. Kaur, E.A. Ling (Eds.).
40. Madeira J.M., Renschler C.J., Mueller B., Hashioka S., Gibson D.L., Klegeris A. Novel protective properties of auranofin: inhibition of human astrocyte cytotoxic secretions and direct neuroprotection. Life Sci. 2013, 92:1072-1080.
41. Makino J., Kamiya T., Hara H., Adachi T. TPA induces the expression of EC-SOD in human monocytic THP-1 cells: involvement of PKC, MEK/ERK and NOX-derived ROS. Free Radic. Res. 2012, 46:637-644.
42. Means A.R., Dedman J.R. Calmodulin-an intracellular calcium receptor. Nature 1980, 285:73-77.
43. Mirabelli C.K., Johnson R.K., Sung C.M., Faucette L., Muirhead K., Crooke S.T. Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. Cancer Res. 1985, 45:32-39.
44. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
45. Muranaka S., Fujita H., Fujiwara T., Ogino T., Sato E.F., Akiyama J., Imada I., Inoue M., Utsumi K. Mechanism and characteristics of stimuli-dependent ROS generation in undifferentiated HL-60 cells. Antioxid. Redox Signal. 2005, 7:1367-1376.
46. Nakaya A., Sagawa M., Muto A., Uchida H., Ikeda Y., Kizaki M. The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-kappaB activity. Leuk. Res. 2011, 35:243-249.
47. Persidsky Y., Ramirez S.H., Haorah J., Kanmogne G.D. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J. Neuroimmune Pharmacol. 2006, 1:223-236.
48. Pocernich C.B., Butterfield D.A. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim. Biophys. Acta 2012, 1822:625-630.
49. Polanski W., Reichmann H., Gille G. Stimulation, protection and regeneration of dopaminergic neurons by 9-methyl-β-carboline: a new anti-Parkinson drug?. Expert. Rev. Neurother. 2011, 11:845-860.
50. Ransohoff R.M., Brown M.A. Innate immunity in the central nervous system. J. Clin. Invest. 2012, 122:1164-1171.
51. Stern I., Wataha J.C., Lewis J.B., Messer R.L., Lockwood P.E., Tseng W.Y. Anti-rheumatic gold compounds as sublethal modulators of monocytic LPS-induced cytokine secretion. Toxicol. in Vitro 2005, 19:365-371.
52. Van Dervort A.L., Doerfler M.E., Stuetz P., Danner R.L. Antagonism of lipopolysaccharide-induced priming of human neutrophils by lipid A analogs. J. Immunol. 1992, 149:359-366.
53. Walz D.T., DiMartino M.J., Griswold D.E., Intoccia A.P., Flanagan T.L. Biologic actions and pharmacokinetic studies of auranofin. Am. J. Med. 1983, 75:90-108.
54. Wong K., Parente J., Prasad K.V., Ng D. Auranofin modulated cytoplasmic free calcium in neutrophils by mobilizing intracellular calcium and inhibiting protein kinase. J. Biol. Chem. 1990, 265:21454-21461.
55. Yamada R., Sano H., Hla T., Hashiramoto A., Fukui W., Miyazaki S., Kohno M., Tsubouchi Y., Kusaka Y., Kondo M. Auranofin inhibits interleukin-1beta-induced transcript of cyclooxygenase-2 on cultured human synoviocytes. Eur. J. Pharmacol. 1999, 385:71-79.
56. Yamamoto N., Izumi Y., Matsuo T., Wakita S., Kume T., Takada-Takatori Y., Sawada H., Akaike A. Elevation of heme oxygenase-1 by proteasome inhibition affords dopaminergic neuroprotection. J. Neurosci. Res. 2010, 88:1934-1942.
57. Yamashita M., Niki H., Yamada M., Watanabe-Kobayashi M., Mue S., Ohuchi K. Dual effects of auranofin on prostaglandin E2 production by rat peritoneal macrophages. Eur. J. Pharmacol. 1997, 325:221-227.
58. Zhang W., Wang T., Pei Z., Miller D.S., Wu X., Block M.L., Wilson B., Zhang W., Zhou Y., Hong J.S., Zhang J. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 2005, 19:533-542.
59. Zilka N., Kazmerova Z., Jadhav S., Neradil P., Madari A., Obetkova D., Bugos O., Novak M. Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways. J. Neuroinflammation 2012, 9:47.